What is King Pharmaceuticals's international — year 3?

King Pharmaceuticals (KG) reported international — year 3 of 2.7% in Q4 2025.

What does international — year 3 mean?

This metric represents the third year of the loss development cycle for the international segment, reflecting the maturation of claims and the stabilization of reserve estimates. At this stage, the majority of short-tail claims are typically settled, allowing for a more accurate assessment of the ultimate loss ratio. It serves as a benchmark for evaluating the long-term profitability of the international insurance portfolio.

King Pharmaceuticals KG International — Year 3

Other product segments

Commercial Auto Liability

18.7%—

General Liability

13.1%—

European Hospital Liability

10.4%—

All other lines

2.7%—

Similar metrics at other companies

CNAInternational — Year 3

11.3%—

AXSInsurance — Year 3

15.3%—

GLREFinancial — Year 3

46.4%-4.4pp

GLREHealth — Year 3

2.4%-0.2pp

EGProperty Insurance — Year three

24.2%+1.7pp

CNAInternational — Year 2

22.6%—

Other financials

Income statement

See full

Revenue$10.2M+1,112%

Net income-$7.4M-1,786%

EPS (diluted)-$0.96-586%

Balance sheet

See full

Cash & equivalents$62.2M+1,724%

Total debt$176.7M—

Total equity$121.4M+2,773%

Total assets$964.2M—

Cash flow

See full

Operating cash flow-$15.1M-1,628%

Valuation

See full

Market cap$70.42M-67.6%

Enterprise value$184.93M-50.0%

P/E1.2×—

P/S1.6×-24.3×

Profitability

See full

Net margin131.5%—

Returns & leverage

See full

Return on equity90.8%—

Debt / equity1.5×—

Where this comes from

Reported directly by King Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:ShortdurationInsuranceContractsHistoricalClaimsDurationYearThree.

The official record: King Pharmaceuticals’s 10-K, filed March 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about King Pharmaceuticals's international — year 3.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI

Claude

Questions, answered.

What is King Pharmaceuticals's international — year 3?: King Pharmaceuticals (KG) reported international — year 3 of 2.7% in Q4 2025.
What does international — year 3 mean?: This metric represents the third year of the loss development cycle for the international segment, reflecting the maturation of claims and the stabilization of reserve estimates. At this stage, the majority of short-tail claims are typically settled, allowing for a more accurate assessment of the ultimate loss ratio. It serves as a benchmark for evaluating the long-term profitability of the international insurance portfolio.